Download PDFPDF

Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    [Error figure 1] Sokal Score Formula
    • Jim CANET, Epidemiologist intern niversity of Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health Research, Bordeaux, France.

    Good Morning,

    I just want to put out a typo in figure (1) : the sokal score formula should be : exp(0.0116*(age - 43.4 ) + ... and not exp(0.0116*(age - 4.34 ) +... .

    If you use 4.34 all you patients will be in "High Risk Group".

    source : Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in « good-risk » chronic granulocytic leukemia. Blood. 1 avr 1984;63(4):789‑99.


    Jim Canet

    Conflict of Interest:
    None declared.